Evidence check: Cardio Risk Check in the context of menopause

The combination of a Cardio Risk Check and menopause is not directly addressed in the provided context. The available information covers pharmacogenetics (CYP2D6, CYP2C19, VKORC1), hormone tests (without specifying cardiovascular markers), and microbiome/longevity tests. It is well established that menopause increases cardiovascular risk due to estrogen decline, but a consumer DNA or biomarker test alone cannot comprehensively assess this risk. Evidence for such tests in this specific context is unclear – there are no clinically validated studies demonstrating direct benefit. A proper Cardio Risk Check should incorporate traditional risk factors (blood pressure, lipids, glucose, smoking, family history) alongside menopausal status. Without integration into a clinical framework, the test's value remains limited. Safety note: Do not rely solely on a consumer genetic test for cardiovascular risk assessment during menopause; consult a healthcare provider.